search
Back to results

A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis (OCTAVE)

Primary Purpose

Ulcerative Colitis

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Placebo
CP690,550
CP-690,550
Sponsored by
Pfizer
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ulcerative Colitis focused on measuring Janus kinase inhibitor, JAK 3 inhibitor, inflammatory bowel disease, ulcerative colitis, OCTAVE, CP-690, 550, tofacitinib, Xeljanz

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subjects who met study entry criteria and completed 8-week induction treatment from Study A3921094 or A3921095
  • Subjects who achieved clinical response in Study A3921094 or A3921095
  • Women of childbearing potential must test negative for pregnancy prior to study enrollment
  • Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
  • Evidence of a personally signed and dated informed consent document(s) indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion Criteria:

  • Subjects who had major protocol violation (as determined by the Sponsor) in Study A3921094 or A3921095
  • Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical findings suggestive of Crohn's disease
  • Subjects who have had surgery for UC or in the opinion of the investigator, are likely to require surgery for UC during the study period.

Sites / Locations

  • Internal Medicine Center, LLC
  • Springhill Memorial Hospital (Endoscopy Only)
  • UCSD Health System - Investigational Drug Pharmacy - Moores Cancer Center
  • UCSD Medical Center
  • Alliance Clinical Research
  • Desert Advanced Imaging
  • Erik Palmer, DO
  • Homan A Zadeh, MD, MPH
  • Hope Square Surgical Center
  • Sharp Rees-Stealy Medical Group, Inc.
  • Clinical Applications Laboratories, Inc
  • San Diego Endoscopy Center
  • Sharp Rees-Stealy Medical Group
  • UCSF Endoscopy Unit at Mount Zion
  • University of California San Francisco
  • Bristol Hospital
  • Connecticut Clinical Research Foundation
  • Endoscopy Center of Connecticut, LLC
  • Endoscopy Center of Connecticut, LLC
  • Gastroenterology Center of Connecticut, PC
  • Medical Research Center of Connecticut, LLC
  • Central Connecticut Endoscopy Center
  • Citrus Surgery & Endoscopy Center (colonoscopy)
  • Nature Coast Clinical Research
  • Suncoast Endoscopy Center (colonoscopy)
  • North Florida Gastroenterology Research, LLC
  • Citrus Ambulatory Surgery Center
  • Internal Medicine Specialists
  • Advanced Gastroenterology Center
  • Advanced Medical Research Center
  • Endoscopy Center
  • Port Orange Urgent Care
  • Florida Medical Clinic, P.A.
  • Florida Medical Clinic, P.A.
  • Georgia Endoscopy Center
  • GI Consultants
  • Emory Healthcare Heart Center
  • Gastroenterology Associates of Central Georgia, LLC
  • Atlanta Gastroenterology Specialists, PC
  • Johns Creek Diagnostic Center
  • Cotton-O'Neal Clinical Research Center Digestive Health
  • Digestive Disease Associates, PA
  • Gastrointestinal Diagnostic Center
  • Digestive Disease Associates, PA
  • Howard County GIDC
  • Saint Joseph Mercy Hospital - Inpatient Pharmacy
  • East Ann Arbor Health and Geriatrics Center - UMHS
  • University of Michigan Health Systems
  • Michigan Clinical Research Unit - UMHS
  • Medical Science Research Building 1 - UMHS
  • Clinical Research Institute of Michigan, LLC
  • Center for Digestive Health
  • Surgical Centers of Michigan
  • Utica Surgery Center (Endoscopy Only)
  • Michigan Heart SJMH
  • Huron Gastroenterology Associates
  • Saint Joseph Mercy Hospital Outpatient Laboratory
  • Mayo Clinic
  • Dartmouth Hitchcock Medical Center
  • AGA Clinical Research Associates, LLC
  • South Jersey Gastroenterology
  • The Endo Center at Voorhees
  • NYU Langone Long Island Clinical Research Associates
  • NYU Langone Nassau Gastroenterology Associates
  • The Private Practice of Simon Lichtiger, MD
  • IBD Center - The Mount Sinai Hospital
  • Icahn School of Medicine at Mount Sinai
  • Columbia University Medical Center
  • CUMC Research Pharmacy
  • Kornbluth, Legnani, George MD, PC
  • University of Rochester
  • Carolina Research, Carolina Digestive Diseases
  • Cleveland Clinic
  • Great Lakes Gastroenterology
  • Mentor Medical Campus
  • The Endoscopy Center of Lake County
  • Regional Gastroenterology Associates of Lancaster, Ltd.
  • Professional Quality Research, Inc.- Austin Gastroenterology PA
  • Austin Endoscopy Center II
  • Austin Gastroenterology PA
  • Houston Hospital for Specialized Surgery (Endoscopy only)
  • Baylor College of Medicine (Baylor Medical Center)
  • Baylor College of Medicine - Baylor Medical Center (Drug Storage)
  • McGovern Medical School -The University of Texas Health Science Center at Houston
  • Memorial Hermann Hospital
  • Digestive Health Specialists of Tyler
  • Alpine Medical Group
  • Wasatch Clinical Research
  • Wasatch Endoscopy Center
  • VCU Health System Digestive Health Center
  • VCU Health System Endoscopy Suite
  • Virginia Commonwealth University
  • The Center for Digestive Health
  • Wisconsin Center for Advanced Research
  • Concord Repatriation General Hospital
  • Liverpool Hospital
  • Eastern Health-Box Hill Hospital
  • Monash Medical Centre
  • AKH Wien, Universitaetsklinik fuer Innere Medizin III
  • GZA St. Vincentius
  • AZ Groeninge
  • UZ Leuven (University Hospital Leuven), Campus Gasthuisberg
  • H-Hartziekenhuis Roeselare-Menen vzw
  • Hospital de Clinicas de Porto Alegre - HCPA
  • University of Alberta Hospital - Walter C. Mackenzie Health Sciences Centre
  • University of Alberta - Zeidler Ledcor Centre
  • McMaster University Medical Center
  • London Health Sciences Centre - University Hospital
  • Montreal General Hospital - McGill University Health Centre
  • Saskatoon City Hospital
  • Royal University Hospital
  • Instituto de Coloproctología ICO S.A.S.
  • University Hospital Center Zagreb
  • Hepato-Gastroenterologie HK, s.r.o.
  • Nemocnice Strakonice, a.s., Interni oddeleni
  • Krajska zdravotni, a.s. Masarykova nemocnice v Usti nad Labem
  • Aalborg Hospital
  • Aarhus University Hospital
  • Bispebjerg Hospital
  • Hvidovre Hospital
  • Odense University Hospital
  • X-Ray Unit, East Tallinn Central Hospital
  • ECG Unit, Innomedica OU and Qualitas AS (ECG Only)
  • Innomedica OU
  • East Tallinn Central Hospital Internal Medical Clinic
  • ECG Unit of West Tallinn Central Hospital
  • West Tallinn Central Hospital
  • X- Ray Department of West Tallinn Central Hospital
  • X-Ray Department of West Tallinn Central Hospital
  • Mammograaf OU (Endoscopy Only)
  • ECG Unit, East Tallinn Central Hospital
  • CHU Amiens PICARDIE - Hopital SUD
  • Hopital Saint Andre
  • Hopital Beaujon
  • Hotel-Dieu CHU Nantes
  • Hopital Saint Antoine - Service de Gastroenterologie
  • Hopital Saint Louis - Service d'hepato-gastoenterologie
  • Hopital Saint Louis
  • C.H.U. de Reims - Hôpital Robert Debré
  • Hopital Nord
  • Universitaetsklinikum Schleswig-Holstein, Campus Kiel
  • Universitaetsmedizin Berlin, Charite Campus Virchow-Klinikum,
  • Universitätsklinikum Halle
  • Medizinische Hochschule Hannover
  • Klinikum Lüneburg/Abteilung Gastroenterologie
  • Gastroenterologische Gemeinschaftspraxis Minden
  • Universitaetsklinikum Ulm
  • Dr Rethy Pal Korhaz-Rendelointezet, III Belgyogyaszat
  • Szent Margit Korhaz - III Belgyogyaszat
  • Peterfy Sandor Utcai Korhaz Rendelointezet es Baleseti Kozpont
  • Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak
  • Pannonia Maganorvosi Centrum Kft.
  • Debreceni Egyetem Klinikai Kozpont, Belgyogyaszati Intezet Gasztroenterologiai Tanszek
  • Bekes Megyei Pandy Kalman Korhaz III. Gasztroenterologiai Osztaly
  • Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz
  • Karolina Korhaz
  • Pecsi Tudomanyegyetem Klinikai Kozpont
  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont, I. Sz. Belgyogyaszati Klinika
  • Javorszky Odon Korhaz
  • Rambam Health Care Campus
  • Rabin Medical Center, Beilinson campus
  • Kaplan Medical Center
  • Istituto Clinico Humanitas IRCSS
  • AOR Villa Sofia-Cervello
  • AOU Mater Domini - U.O. Fisiopatologia Digestiva
  • Aichi Medical University Hospital
  • Hokkaido P.W.F.A.C Sapporo-Kosei general Hospital
  • The Hospital of Hyogo College of Medicine
  • National Hospital Organization Mito Medical Center
  • Sameshima Hospital
  • Kuniyoshi Hospital
  • National Hospital Organization Sendai Medical Center
  • Osaka Medical College Hospital
  • Shiga University of Medical Science Hospital
  • Tokyo Medical And Dental University Hospital, Faculty of Medicine
  • Tokai University Hachioji Hospital
  • Kitasato University Kitasato Institute Hospital
  • NTT Medical Center Tokyo
  • Showa University Hospital
  • Keio University Hospital
  • Chiba University Hospital
  • Toho University Sakura Medical Center
  • Kurume University Hospital
  • Hiroshima University Hospital
  • Osaka City University Hospital
  • Hanyang University Guri Hospital
  • KyungHee University Hospital
  • Gachon University Gil Medical Center
  • Kyung Hee University Hospital
  • Samsung Medical Center
  • Seoul National University Hospital,
  • ECG room Clinic Linezers (ECG only) Riga East University Hospital
  • X-Ray Department, Clinic Linezers (radiology only)
  • Digestive Diseases Center GASTRO
  • VU University Medical Center (VUMC)
  • Academic Medical Centre
  • University Medical Center Groningen (UMCG)
  • Leiden University Medical Center (LUMC)
  • Shakespeare Specialist Group
  • Tauranga Hospital
  • Christchurch Hospital
  • Auckland City Hospital
  • Southern District Health Board
  • Waikato Hospital
  • P3 Research Limited
  • Pacific Radiology (X-rays only)
  • Bowen Hospital
  • Centrum Medyczne Szpital Sw. Rodziny Sp. z o. o.
  • Centrum Endoskopii Zabiegowej, Poradnia Chorob Jelitowych, Szpital Uniwersytecki nr 2 im
  • Klinika Chorob Wewnetrznych i Gastroenterologii z
  • H-T. Centrum Medyczne - ENDOTERAPIA
  • Gabinet Lekarski - Janusz Rudzinski
  • Gabinet Endoskopii Przewodu Pokarmowego
  • Oddzial Kliniczny Gastroenterologii Ogólnej i Onkologicznej, Uniwersytecki Szpital
  • Endoskopia Sp. Z O.O.
  • Nzoz Vivamed
  • Lexmedica
  • Cabinet Particular Policlinic Algomed Srl
  • Spitalul Universitar de Urgenta Bucharest
  • Municipal Institution of Healthcare City Clinical Hospital 12,
  • Federal state budget institution "State scientific centre of coloproctology"
  • State Budget Institution of Healthcare Nizhniy Novgorod Regional Clinical Hospital named after N. A.
  • Federal state Institution "Sibirian regional Medical centre of Federal Medicobiologic Agency",
  • Municipal Budget Institution of Healthcare of Novosibirsk " City Clinical Hospital No 12"
  • State Budget Educational Institution of Higher Professional Education
  • Federal State Budgetary Institution "Scientific Research Institute of Physiology and Fundamental
  • Non-State Healthcare Institution "Road Clinical Hospital at the station Samara"
  • Limited Liability Company Medical Company "Hepatolog"
  • Limited Liability Company Medical Company "Hepatolog"
  • Samara Diagnostic center, X-ray Department
  • State budget institution of healthcare of Yaroslavl region Regional clinical hospital
  • Clinical Centre of Serbia, Clinic for Gastroenterology and Hepatology
  • Clinical Hospital Centre Zvezdara
  • Military Medical Academy Belgrade
  • Clinical Centre of Kragujevac
  • Clinical Centre of Vojvodina, Clinic for Gastroenterology and Hepatology
  • Clinical Centre of Vojvodina, Emergency Internal Medicine Division
  • "General Hospital ""Djordje Joanovic""
  • Medak s.r.o.
  • KM Management spol. s.r.o.
  • Aura SA, s.r.o.
  • Gastro I., s.r.o.
  • Dr John Philip Wright
  • Chris Hani Baragwanath Academic Hospital
  • Panorama MediClinic
  • Louis Leipoldt Medical Centre
  • Endocare Research Centre
  • Hospital Universitari de Bellvitge, Servicio de Digestivo
  • Hospital Clinic i Provincial de Barcelona
  • Hospital Clinico San Carlos
  • Hospital Universitario de Fuenlabrada
  • National Taiwan University Hospital
  • Internal Medicine Center of Crimean Republic Institution"Clinical Territorial Medical Community"
  • Regional Municipal Institution "Chernivtsi Regional Clinical Hospital"
  • Regional Municipal Institution Chernivtsi Regional Clinical Hospital,
  • State Institution "Institute of Gastroenterology of the National Academy of Medical Sciences of
  • Municipal Healthcare Institution Kharkiv City Clinical Hospital #2, Proctology Department
  • State Institution "National L.T. Malaya Therapy Institute of National Academy of
  • Kyiv Municipal Clinical Hospital #18, Proctology Department
  • LTD "St. Paraskeva Medical Center"
  • Municipal City Clinical Hospital of the Emergency Medical Care, 1-st Therapy Department of hospital,
  • SI "Railway Hospital of the SI "Odesa Railway"", Polyclinic Department,
  • Municipal Institution "Odesa Regional Clinical Hospital"
  • SI "District Clin. Hosp.of Uzhgorod station (STSA "Lviv Railway", Therapy Dep., SBHEI "Uzhgorod Nat.
  • Vinnytsia Regional Clinical Hospital for Invalids of the Great Patriotic War, Therapy Department #2,
  • Motor-Sich clinic, LLC
  • Minicipal Institution City Hospital 7, Therapevtic Department,
  • Municipal Institution "City Hospital #7", Zaporizhzhia State Medical University
  • Addenbrooke's Hospital-Cambridge University Hospitals NHS Foundation Trust
  • Department of Gastroenterology, Old Building
  • University College Hospital
  • NWLH NHS trust
  • The North West London Hospitals NHS Trust
  • Norfolk and Norwich University Hospital
  • Addenbrooke's Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Placebo Comparator

Experimental

Experimental

Arm Label

Placebo Comparator

CP-690,550 5 mg Arm

CP-690,550 10 mg Arm

Arm Description

Outcomes

Primary Outcome Measures

Percentage of Participants In Remission at Week 52
Remission in participants was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of ulcerative colitis (UC). It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and physician global assessment (PGA), each subscore graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12 where higher score indicating higher disease severity.

Secondary Outcome Measures

Percentage of Participants With Mucosal Healing at Week 52
Mucosal healing in participants was defined by mayo endoscopic subscore of 0 or 1. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher subscores indicating higher disease severity.
Percentage of Participants With Sustained Steroid-Free Remission (Defined as Being in Remission and Steroid-Free at Both Week 24 and 52), Among Participants With Remission at Baseline
Sustained steroid-free remission was defined by being in remission and steroid-free at both Week 24 and Week 52. Steroid-free remission was defined by being in remission, in addition to no requirement of any treatment with steroid for at least 4 weeks prior to the visit. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with sustained steroid-free remission (among participants with remission at baseline) were reported in this outcome measure.
Percentage of Participants in Remission at Week 24
Remission in participants was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher subscores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
Percentage of Participants in Sustained Remission
Sustained remission in participants was defined by being in remission at both Week 24 and Week 52. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher subscores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher score indicating higher disease severity.
Percentage of Participants With Mucosal Healing at Week 24
Mucosal healing in participants was defined by a mayo endoscopic subscore of 0 or 1. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher scores indicating higher disease severity.
Percentage of Participants With Sustained Mucosal Healing
Sustained mucosal healing in participants was defined by achieving mayo endoscopic subscore of 0 or 1 at both Week 24 and Week 52. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher scores indicating higher disease severity.
Percentage of Participants With Mucosal Healing at Week 24 and 52, Among Participants With Mucosal Healing at Baseline
Mucosal healing in participants was defined as achieving mayo endoscopic subscore of 0 or 1. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher scores indicating higher disease severity.
Percentage of Participants With Sustained Mucosal Healing, Among Participants With Mucosal Healing at Baseline
Sustained mucosal healing in participants was defined by achieving mayo endoscopic subscore of 0 or 1 at both Week 24 and Week 52. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher scores indicating higher disease severity.
Percentage of Participants With Clinical Response at Week 24 and 52
Clinical response was defined by a decrease from induction study (A3921094 [NCT01465763] or A3921095 [NCT01458951]) baseline in Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the rectal bleeding subscore of at least 1 point, or an absolute rectal bleeding subscore of 0 or 1. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with clinical response at Week 24 and 52 have been reported in this outcome measure.
Percentage of Participants With Sustained Clinical Response
Sustained clinical response in participants was defined as showing clinical response at both Week 24 and Week 52. Clinical response was defined by a decrease from induction study (A3921094 [NCT01465763] or A3921095 [NCT01458951]) baseline in mayo score of at least 3 points and at least 30%, with an accompanying decrease in the rectal bleeding subscore of at least 1 point, or an absolute rectal bleeding subscore of 0 or 1. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with sustained clinical response are reported in this outcome measure.
Percentage of Participants in Clinical Remission at Week 24 and 52
Clinical remission in participants was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
Percentage of Participants in Sustained Clinical Remission
Sustained clinical remission in participants was defined as being in clinical remission at both Week 24 and Week 52. Clinical remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
Percentage of Participants in Deep Remission at Week 24 and 52
Deep remission in participants was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and 0 subscore for both rectal bleeding and endoscopic subscores. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
Percentage of Participants in Sustained Deep Remission
Sustained deep remission was defined by being in deep remission at both Week 24 and Week 52. Deep remission in participants was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and 0 subscore for both rectal bleeding and endoscopic subscores. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
Percentage of Participants in Symptomatic Remission at Week 24 and 52
Symptomatic remission in participants was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and 0 subscore for both rectal bleeding and stool frequency. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 sub-scores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
Percentage of Participants in Sustained Symptomatic Remission
Sustained symptomatic remission in participants was defined as being in symptomatic remission at both Week 24 and Week 52. Symptomatic remission was defined as a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and 0 subscore for both rectal bleeding and stool frequency. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
Percentage of Participants in Endoscopic Remission at Week 24 and 52
Endoscopic remission in participants was defined as a mayo endoscopic subscore of 0. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher subscores indicating higher disease severity.
Percentage of Participants in Sustained Endoscopic Remission
Sustained endoscopic remission in participants was defined as being in endoscopic remission at both Week 24 and Week 52. Endoscopic remission was defined by a mayo endoscopic subscore of 0. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher subscores indicating higher disease severity.
Total Mayo Score at Baseline, Week 24 and 52
Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
Change From Baseline in Total Mayo Score at Week 24 and 52
Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Change from baseline in total mayo score at Week 24 and 52 was reported.
Percentage of Participants in Remission, Among Participants With Remission at Baseline
Remission in participants was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher score indicating higher disease severity.
Percentage of Participants in Sustained Remission, Among Participants With Remission at Baseline
Sustained remission in participants was defined by being in remission at both Week 24 and Week 52. Remission was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher score indicating higher disease severity.
Percentage of Participants in Steroid-free Remission, Among Participants in Remission at Baseline
Steroid-free remission was defined by being in remission, in addition to no requirement of any treatment with steroid for at least 4 weeks prior to the visit. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants in steroid-free remission were reported in this outcome measure.
Percentage of Participants in Steroid-Free Remission, Among Participants Receiving Steroids at Baseline
Steroid-free remission was defined by being in remission, in addition to no requirement of any treatment with steroid for at least 4 weeks prior to the visit. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with steroid-free remission were reported in this outcome measure.
Percentage of Participants in Sustained Steroid-Free Remission, Among Participants Receiving Steroids at Baseline
Sustained steroid-free remission was defined by being in remission and steroid-free at both Week 24 and Week 52. Steroid-free remission was defined by being in remission, in addition to no requirement of any treatment with steroid for at least 4 weeks prior to the visit. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with sustained steroid-free remission were reported in this outcome measure.

Full Information

First Posted
October 21, 2011
Last Updated
April 7, 2017
Sponsor
Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT01458574
Brief Title
A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis
Acronym
OCTAVE
Official Title
A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As A Maintenance Therapy In Subjects With Ulcerative Colitis
Study Type
Interventional

2. Study Status

Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
July 20, 2012 (Actual)
Primary Completion Date
May 27, 2016 (Actual)
Study Completion Date
May 27, 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pfizer

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The study proposes to assess whether compared to placebo, CP-690,550 is effective, safe, and tolerable maintenance therapy in subjects with Ulcerative Colitis (UC). The study proposes to assess whether compared to placebo, CP-690,550 maintenance therapy more effectively achieves mucosal healing and improves quality of life in subjects with UC.The study proposes to assess CP-690,550 pharmacokinetic exposure during maintenance therapy in subjects over the age of 18 years with UC.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ulcerative Colitis
Keywords
Janus kinase inhibitor, JAK 3 inhibitor, inflammatory bowel disease, ulcerative colitis, OCTAVE, CP-690, 550, tofacitinib, Xeljanz

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
593 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo Comparator
Arm Type
Placebo Comparator
Arm Title
CP-690,550 5 mg Arm
Arm Type
Experimental
Arm Title
CP-690,550 10 mg Arm
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo 10 mg orally (PO) twice a day (BID)
Intervention Type
Drug
Intervention Name(s)
CP690,550
Intervention Description
CP-690,550 5 mg orally (PO) twice a day (BID)
Intervention Type
Drug
Intervention Name(s)
CP-690,550
Intervention Description
CP-690,550 10 mg orally (PO) twice a day (BID)
Primary Outcome Measure Information:
Title
Percentage of Participants In Remission at Week 52
Description
Remission in participants was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of ulcerative colitis (UC). It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and physician global assessment (PGA), each subscore graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12 where higher score indicating higher disease severity.
Time Frame
Week 52
Secondary Outcome Measure Information:
Title
Percentage of Participants With Mucosal Healing at Week 52
Description
Mucosal healing in participants was defined by mayo endoscopic subscore of 0 or 1. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher subscores indicating higher disease severity.
Time Frame
Week 52
Title
Percentage of Participants With Sustained Steroid-Free Remission (Defined as Being in Remission and Steroid-Free at Both Week 24 and 52), Among Participants With Remission at Baseline
Description
Sustained steroid-free remission was defined by being in remission and steroid-free at both Week 24 and Week 52. Steroid-free remission was defined by being in remission, in addition to no requirement of any treatment with steroid for at least 4 weeks prior to the visit. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with sustained steroid-free remission (among participants with remission at baseline) were reported in this outcome measure.
Time Frame
Week 24, 52
Title
Percentage of Participants in Remission at Week 24
Description
Remission in participants was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher subscores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
Time Frame
Week 24
Title
Percentage of Participants in Sustained Remission
Description
Sustained remission in participants was defined by being in remission at both Week 24 and Week 52. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher subscores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher score indicating higher disease severity.
Time Frame
Week 24, 52
Title
Percentage of Participants With Mucosal Healing at Week 24
Description
Mucosal healing in participants was defined by a mayo endoscopic subscore of 0 or 1. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher scores indicating higher disease severity.
Time Frame
Week 24
Title
Percentage of Participants With Sustained Mucosal Healing
Description
Sustained mucosal healing in participants was defined by achieving mayo endoscopic subscore of 0 or 1 at both Week 24 and Week 52. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher scores indicating higher disease severity.
Time Frame
Week 24, 52
Title
Percentage of Participants With Mucosal Healing at Week 24 and 52, Among Participants With Mucosal Healing at Baseline
Description
Mucosal healing in participants was defined as achieving mayo endoscopic subscore of 0 or 1. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher scores indicating higher disease severity.
Time Frame
Week 24, 52
Title
Percentage of Participants With Sustained Mucosal Healing, Among Participants With Mucosal Healing at Baseline
Description
Sustained mucosal healing in participants was defined by achieving mayo endoscopic subscore of 0 or 1 at both Week 24 and Week 52. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher scores indicating higher disease severity.
Time Frame
Week 24, 52
Title
Percentage of Participants With Clinical Response at Week 24 and 52
Description
Clinical response was defined by a decrease from induction study (A3921094 [NCT01465763] or A3921095 [NCT01458951]) baseline in Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the rectal bleeding subscore of at least 1 point, or an absolute rectal bleeding subscore of 0 or 1. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with clinical response at Week 24 and 52 have been reported in this outcome measure.
Time Frame
Week 24, 52
Title
Percentage of Participants With Sustained Clinical Response
Description
Sustained clinical response in participants was defined as showing clinical response at both Week 24 and Week 52. Clinical response was defined by a decrease from induction study (A3921094 [NCT01465763] or A3921095 [NCT01458951]) baseline in mayo score of at least 3 points and at least 30%, with an accompanying decrease in the rectal bleeding subscore of at least 1 point, or an absolute rectal bleeding subscore of 0 or 1. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with sustained clinical response are reported in this outcome measure.
Time Frame
Week 24, 52
Title
Percentage of Participants in Clinical Remission at Week 24 and 52
Description
Clinical remission in participants was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
Time Frame
Week 24, 52
Title
Percentage of Participants in Sustained Clinical Remission
Description
Sustained clinical remission in participants was defined as being in clinical remission at both Week 24 and Week 52. Clinical remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
Time Frame
Week 24, 52
Title
Percentage of Participants in Deep Remission at Week 24 and 52
Description
Deep remission in participants was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and 0 subscore for both rectal bleeding and endoscopic subscores. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
Time Frame
Week 24, 52
Title
Percentage of Participants in Sustained Deep Remission
Description
Sustained deep remission was defined by being in deep remission at both Week 24 and Week 52. Deep remission in participants was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and 0 subscore for both rectal bleeding and endoscopic subscores. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
Time Frame
Week 24, 52
Title
Percentage of Participants in Symptomatic Remission at Week 24 and 52
Description
Symptomatic remission in participants was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and 0 subscore for both rectal bleeding and stool frequency. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 sub-scores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
Time Frame
Week 24, 52
Title
Percentage of Participants in Sustained Symptomatic Remission
Description
Sustained symptomatic remission in participants was defined as being in symptomatic remission at both Week 24 and Week 52. Symptomatic remission was defined as a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and 0 subscore for both rectal bleeding and stool frequency. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
Time Frame
Week 24, 52
Title
Percentage of Participants in Endoscopic Remission at Week 24 and 52
Description
Endoscopic remission in participants was defined as a mayo endoscopic subscore of 0. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher subscores indicating higher disease severity.
Time Frame
Week 24, 52
Title
Percentage of Participants in Sustained Endoscopic Remission
Description
Sustained endoscopic remission in participants was defined as being in endoscopic remission at both Week 24 and Week 52. Endoscopic remission was defined by a mayo endoscopic subscore of 0. The mayo endoscopic subscore consisted of the findings of centrally read flexible sigmoidoscopy, graded from 0 to 3 with higher subscores indicating higher disease severity.
Time Frame
Week 24, 52
Title
Total Mayo Score at Baseline, Week 24 and 52
Description
Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity.
Time Frame
Baseline, Week 24, 52
Title
Change From Baseline in Total Mayo Score at Week 24 and 52
Description
Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Change from baseline in total mayo score at Week 24 and 52 was reported.
Time Frame
Baseline, Week 24, 52
Title
Percentage of Participants in Remission, Among Participants With Remission at Baseline
Description
Remission in participants was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher score indicating higher disease severity.
Time Frame
Week 24, 52
Title
Percentage of Participants in Sustained Remission, Among Participants With Remission at Baseline
Description
Sustained remission in participants was defined by being in remission at both Week 24 and Week 52. Remission was defined as a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher score indicating higher disease severity.
Time Frame
Week 24, 52
Title
Percentage of Participants in Steroid-free Remission, Among Participants in Remission at Baseline
Description
Steroid-free remission was defined by being in remission, in addition to no requirement of any treatment with steroid for at least 4 weeks prior to the visit. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants in steroid-free remission were reported in this outcome measure.
Time Frame
Week 24, 52
Title
Percentage of Participants in Steroid-Free Remission, Among Participants Receiving Steroids at Baseline
Description
Steroid-free remission was defined by being in remission, in addition to no requirement of any treatment with steroid for at least 4 weeks prior to the visit. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with steroid-free remission were reported in this outcome measure.
Time Frame
Week 24, 52
Title
Percentage of Participants in Sustained Steroid-Free Remission, Among Participants Receiving Steroids at Baseline
Description
Sustained steroid-free remission was defined by being in remission and steroid-free at both Week 24 and Week 52. Steroid-free remission was defined by being in remission, in addition to no requirement of any treatment with steroid for at least 4 weeks prior to the visit. Remission was defined by a total mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating higher disease severity. These subscores were summed up to give a total score range of 0 to 12, where higher scores indicating higher disease severity. Percentage of participants with sustained steroid-free remission were reported in this outcome measure.
Time Frame
Week 24, 52

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects who met study entry criteria and completed 8-week induction treatment from Study A3921094 or A3921095 Subjects who achieved clinical response in Study A3921094 or A3921095 Women of childbearing potential must test negative for pregnancy prior to study enrollment Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures Evidence of a personally signed and dated informed consent document(s) indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Exclusion Criteria: Subjects who had major protocol violation (as determined by the Sponsor) in Study A3921094 or A3921095 Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical findings suggestive of Crohn's disease Subjects who have had surgery for UC or in the opinion of the investigator, are likely to require surgery for UC during the study period.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pfizer CT.gov Call Center
Organizational Affiliation
Pfizer
Official's Role
Study Director
Facility Information:
Facility Name
Internal Medicine Center, LLC
City
Mobile
State/Province
Alabama
ZIP/Postal Code
36608
Country
United States
Facility Name
Springhill Memorial Hospital (Endoscopy Only)
City
Mobile
State/Province
Alabama
ZIP/Postal Code
36608
Country
United States
Facility Name
UCSD Health System - Investigational Drug Pharmacy - Moores Cancer Center
City
La Jolla
State/Province
California
ZIP/Postal Code
92037-0845
Country
United States
Facility Name
UCSD Medical Center
City
La Jolla
State/Province
California
ZIP/Postal Code
92093
Country
United States
Facility Name
Alliance Clinical Research
City
Oceanside
State/Province
California
ZIP/Postal Code
92056
Country
United States
Facility Name
Desert Advanced Imaging
City
Palm Springs
State/Province
California
ZIP/Postal Code
92262
Country
United States
Facility Name
Erik Palmer, DO
City
Palm Springs
State/Province
California
ZIP/Postal Code
92262
Country
United States
Facility Name
Homan A Zadeh, MD, MPH
City
Palm Springs
State/Province
California
ZIP/Postal Code
92262
Country
United States
Facility Name
Hope Square Surgical Center
City
Rancho Mirage
State/Province
California
ZIP/Postal Code
92270
Country
United States
Facility Name
Sharp Rees-Stealy Medical Group, Inc.
City
San Diego
State/Province
California
ZIP/Postal Code
92101
Country
United States
Facility Name
Clinical Applications Laboratories, Inc
City
San Diego
State/Province
California
ZIP/Postal Code
92103
Country
United States
Facility Name
San Diego Endoscopy Center
City
San Diego
State/Province
California
ZIP/Postal Code
92103
Country
United States
Facility Name
Sharp Rees-Stealy Medical Group
City
San Diego
State/Province
California
ZIP/Postal Code
92123
Country
United States
Facility Name
UCSF Endoscopy Unit at Mount Zion
City
San Francisco
State/Province
California
ZIP/Postal Code
94115
Country
United States
Facility Name
University of California San Francisco
City
San Francisco
State/Province
California
ZIP/Postal Code
94115
Country
United States
Facility Name
Bristol Hospital
City
Bristol
State/Province
Connecticut
ZIP/Postal Code
06010
Country
United States
Facility Name
Connecticut Clinical Research Foundation
City
Bristol
State/Province
Connecticut
ZIP/Postal Code
06010
Country
United States
Facility Name
Endoscopy Center of Connecticut, LLC
City
Guilford
State/Province
Connecticut
ZIP/Postal Code
06437
Country
United States
Facility Name
Endoscopy Center of Connecticut, LLC
City
Hamden
State/Province
Connecticut
ZIP/Postal Code
06518
Country
United States
Facility Name
Gastroenterology Center of Connecticut, PC
City
Hamden
State/Province
Connecticut
ZIP/Postal Code
06518
Country
United States
Facility Name
Medical Research Center of Connecticut, LLC
City
Hamden
State/Province
Connecticut
ZIP/Postal Code
06518
Country
United States
Facility Name
Central Connecticut Endoscopy Center
City
Plainville
State/Province
Connecticut
ZIP/Postal Code
06062
Country
United States
Facility Name
Citrus Surgery & Endoscopy Center (colonoscopy)
City
Crystal River
State/Province
Florida
ZIP/Postal Code
34429
Country
United States
Facility Name
Nature Coast Clinical Research
City
Inverness
State/Province
Florida
ZIP/Postal Code
34452
Country
United States
Facility Name
Suncoast Endoscopy Center (colonoscopy)
City
Inverness
State/Province
Florida
ZIP/Postal Code
34453
Country
United States
Facility Name
North Florida Gastroenterology Research, LLC
City
Orange Park
State/Province
Florida
ZIP/Postal Code
32073
Country
United States
Facility Name
Citrus Ambulatory Surgery Center
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Facility Name
Internal Medicine Specialists
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Facility Name
Advanced Gastroenterology Center
City
Port Orange
State/Province
Florida
ZIP/Postal Code
32127
Country
United States
Facility Name
Advanced Medical Research Center
City
Port Orange
State/Province
Florida
ZIP/Postal Code
32127
Country
United States
Facility Name
Endoscopy Center
City
Port Orange
State/Province
Florida
ZIP/Postal Code
32127
Country
United States
Facility Name
Port Orange Urgent Care
City
Port Orange
State/Province
Florida
ZIP/Postal Code
32127
Country
United States
Facility Name
Florida Medical Clinic, P.A.
City
Zephyhills
State/Province
Florida
ZIP/Postal Code
33542
Country
United States
Facility Name
Florida Medical Clinic, P.A.
City
Zephyrhills
State/Province
Florida
ZIP/Postal Code
33542
Country
United States
Facility Name
Georgia Endoscopy Center
City
Alpharetta
State/Province
Georgia
ZIP/Postal Code
30005
Country
United States
Facility Name
GI Consultants
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30342
Country
United States
Facility Name
Emory Healthcare Heart Center
City
Johns Creek
State/Province
Georgia
ZIP/Postal Code
30097
Country
United States
Facility Name
Gastroenterology Associates of Central Georgia, LLC
City
Macon
State/Province
Georgia
ZIP/Postal Code
31201
Country
United States
Facility Name
Atlanta Gastroenterology Specialists, PC
City
Suwanee
State/Province
Georgia
ZIP/Postal Code
30024
Country
United States
Facility Name
Johns Creek Diagnostic Center
City
Suwanee
State/Province
Georgia
ZIP/Postal Code
30024
Country
United States
Facility Name
Cotton-O'Neal Clinical Research Center Digestive Health
City
Topeka
State/Province
Kansas
ZIP/Postal Code
66606
Country
United States
Facility Name
Digestive Disease Associates, PA
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21229
Country
United States
Facility Name
Gastrointestinal Diagnostic Center
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21229
Country
United States
Facility Name
Digestive Disease Associates, PA
City
Catonsville
State/Province
Maryland
ZIP/Postal Code
21228
Country
United States
Facility Name
Howard County GIDC
City
Columbia
State/Province
Maryland
ZIP/Postal Code
21044
Country
United States
Facility Name
Saint Joseph Mercy Hospital - Inpatient Pharmacy
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48106
Country
United States
Facility Name
East Ann Arbor Health and Geriatrics Center - UMHS
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109-2701
Country
United States
Facility Name
University of Michigan Health Systems
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109-5000
Country
United States
Facility Name
Michigan Clinical Research Unit - UMHS
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109-5872
Country
United States
Facility Name
Medical Science Research Building 1 - UMHS
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Facility Name
Clinical Research Institute of Michigan, LLC
City
Chesterfield
State/Province
Michigan
ZIP/Postal Code
48047
Country
United States
Facility Name
Center for Digestive Health
City
Troy
State/Province
Michigan
ZIP/Postal Code
48098
Country
United States
Facility Name
Surgical Centers of Michigan
City
Troy
State/Province
Michigan
ZIP/Postal Code
48098
Country
United States
Facility Name
Utica Surgery Center (Endoscopy Only)
City
Utica
State/Province
Michigan
ZIP/Postal Code
48317
Country
United States
Facility Name
Michigan Heart SJMH
City
Ypsilanti
State/Province
Michigan
ZIP/Postal Code
48106
Country
United States
Facility Name
Huron Gastroenterology Associates
City
Ypsilanti
State/Province
Michigan
ZIP/Postal Code
48197
Country
United States
Facility Name
Saint Joseph Mercy Hospital Outpatient Laboratory
City
Ypsilanti
State/Province
Michigan
ZIP/Postal Code
48197
Country
United States
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Facility Name
Dartmouth Hitchcock Medical Center
City
Lebanon
State/Province
New Hampshire
ZIP/Postal Code
03756
Country
United States
Facility Name
AGA Clinical Research Associates, LLC
City
Egg Harbour Township
State/Province
New Jersey
ZIP/Postal Code
08234
Country
United States
Facility Name
South Jersey Gastroenterology
City
Marlton
State/Province
New Jersey
ZIP/Postal Code
08053
Country
United States
Facility Name
The Endo Center at Voorhees
City
Vorhees
State/Province
New Jersey
ZIP/Postal Code
08043
Country
United States
Facility Name
NYU Langone Long Island Clinical Research Associates
City
Great Neck
State/Province
New York
ZIP/Postal Code
11021
Country
United States
Facility Name
NYU Langone Nassau Gastroenterology Associates
City
Great Neck
State/Province
New York
ZIP/Postal Code
11021
Country
United States
Facility Name
The Private Practice of Simon Lichtiger, MD
City
New York
State/Province
New York
ZIP/Postal Code
10028
Country
United States
Facility Name
IBD Center - The Mount Sinai Hospital
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Facility Name
Icahn School of Medicine at Mount Sinai
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Facility Name
Columbia University Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Facility Name
CUMC Research Pharmacy
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Facility Name
Kornbluth, Legnani, George MD, PC
City
New York
State/Province
New York
ZIP/Postal Code
10128
Country
United States
Facility Name
University of Rochester
City
Rochester
State/Province
New York
ZIP/Postal Code
14642
Country
United States
Facility Name
Carolina Research, Carolina Digestive Diseases
City
Greenville
State/Province
North Carolina
ZIP/Postal Code
27834
Country
United States
Facility Name
Cleveland Clinic
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195-0001
Country
United States
Facility Name
Great Lakes Gastroenterology
City
Mentor
State/Province
Ohio
ZIP/Postal Code
44060
Country
United States
Facility Name
Mentor Medical Campus
City
Mentor
State/Province
Ohio
ZIP/Postal Code
44060
Country
United States
Facility Name
The Endoscopy Center of Lake County
City
Mentor
State/Province
Ohio
ZIP/Postal Code
44060
Country
United States
Facility Name
Regional Gastroenterology Associates of Lancaster, Ltd.
City
Lancaster
State/Province
Pennsylvania
ZIP/Postal Code
17604
Country
United States
Facility Name
Professional Quality Research, Inc.- Austin Gastroenterology PA
City
Austin
State/Province
Texas
ZIP/Postal Code
78705
Country
United States
Facility Name
Austin Endoscopy Center II
City
Austin
State/Province
Texas
ZIP/Postal Code
78745
Country
United States
Facility Name
Austin Gastroenterology PA
City
Austin
State/Province
Texas
ZIP/Postal Code
78745
Country
United States
Facility Name
Houston Hospital for Specialized Surgery (Endoscopy only)
City
Houston
State/Province
Texas
ZIP/Postal Code
77004
Country
United States
Facility Name
Baylor College of Medicine (Baylor Medical Center)
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Baylor College of Medicine - Baylor Medical Center (Drug Storage)
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
McGovern Medical School -The University of Texas Health Science Center at Houston
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Memorial Hermann Hospital
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Digestive Health Specialists of Tyler
City
Tyler
State/Province
Texas
ZIP/Postal Code
75701
Country
United States
Facility Name
Alpine Medical Group
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84102
Country
United States
Facility Name
Wasatch Clinical Research
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84107
Country
United States
Facility Name
Wasatch Endoscopy Center
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84124
Country
United States
Facility Name
VCU Health System Digestive Health Center
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23298
Country
United States
Facility Name
VCU Health System Endoscopy Suite
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23298
Country
United States
Facility Name
Virginia Commonwealth University
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23298
Country
United States
Facility Name
The Center for Digestive Health
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53215
Country
United States
Facility Name
Wisconsin Center for Advanced Research
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53215
Country
United States
Facility Name
Concord Repatriation General Hospital
City
Concord
State/Province
New South Wales
ZIP/Postal Code
2139
Country
Australia
Facility Name
Liverpool Hospital
City
Liverpool
State/Province
New South Wales
ZIP/Postal Code
2170
Country
Australia
Facility Name
Eastern Health-Box Hill Hospital
City
Box Hill
State/Province
Victoria
ZIP/Postal Code
3128
Country
Australia
Facility Name
Monash Medical Centre
City
Clayton
State/Province
Victoria
ZIP/Postal Code
3168
Country
Australia
Facility Name
AKH Wien, Universitaetsklinik fuer Innere Medizin III
City
Wien
State/Province
Vienna
ZIP/Postal Code
1090
Country
Austria
Facility Name
GZA St. Vincentius
City
Antwerpen
ZIP/Postal Code
2018
Country
Belgium
Facility Name
AZ Groeninge
City
Kortrijk
ZIP/Postal Code
8500
Country
Belgium
Facility Name
UZ Leuven (University Hospital Leuven), Campus Gasthuisberg
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Facility Name
H-Hartziekenhuis Roeselare-Menen vzw
City
Roeselare
ZIP/Postal Code
8800
Country
Belgium
Facility Name
Hospital de Clinicas de Porto Alegre - HCPA
City
Porto Alegre
State/Province
Rio Grande Do Sul
ZIP/Postal Code
90035-003
Country
Brazil
Facility Name
University of Alberta Hospital - Walter C. Mackenzie Health Sciences Centre
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 2B7
Country
Canada
Facility Name
University of Alberta - Zeidler Ledcor Centre
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 2X8
Country
Canada
Facility Name
McMaster University Medical Center
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8N 3Z5
Country
Canada
Facility Name
London Health Sciences Centre - University Hospital
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 5A5
Country
Canada
Facility Name
Montreal General Hospital - McGill University Health Centre
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3G 1A4
Country
Canada
Facility Name
Saskatoon City Hospital
City
Saskatoon
State/Province
Saskatchewan
ZIP/Postal Code
S7K 0M7
Country
Canada
Facility Name
Royal University Hospital
City
Saskatoon
State/Province
Saskatchewan
ZIP/Postal Code
S7N 0W8
Country
Canada
Facility Name
Instituto de Coloproctología ICO S.A.S.
City
Medellin
State/Province
Antioquia
ZIP/Postal Code
00000
Country
Colombia
Facility Name
University Hospital Center Zagreb
City
Zagreb
ZIP/Postal Code
10 000
Country
Croatia
Facility Name
Hepato-Gastroenterologie HK, s.r.o.
City
Hradec Kralove
ZIP/Postal Code
500 12
Country
Czech Republic
Facility Name
Nemocnice Strakonice, a.s., Interni oddeleni
City
Strakonice
ZIP/Postal Code
386 29
Country
Czech Republic
Facility Name
Krajska zdravotni, a.s. Masarykova nemocnice v Usti nad Labem
City
Usti nad Labem
ZIP/Postal Code
40113
Country
Czech Republic
Facility Name
Aalborg Hospital
City
Aalborg
ZIP/Postal Code
9000
Country
Denmark
Facility Name
Aarhus University Hospital
City
Aarhus C
ZIP/Postal Code
8000
Country
Denmark
Facility Name
Bispebjerg Hospital
City
Copenhagen NV
ZIP/Postal Code
2400
Country
Denmark
Facility Name
Hvidovre Hospital
City
Hvidovre
ZIP/Postal Code
2650
Country
Denmark
Facility Name
Odense University Hospital
City
Odense C
ZIP/Postal Code
5000
Country
Denmark
Facility Name
X-Ray Unit, East Tallinn Central Hospital
City
Tallinn
ZIP/Postal Code
101 38
Country
Estonia
Facility Name
ECG Unit, Innomedica OU and Qualitas AS (ECG Only)
City
Tallinn
ZIP/Postal Code
10117
Country
Estonia
Facility Name
Innomedica OU
City
Tallinn
ZIP/Postal Code
10117
Country
Estonia
Facility Name
East Tallinn Central Hospital Internal Medical Clinic
City
Tallinn
ZIP/Postal Code
10138
Country
Estonia
Facility Name
ECG Unit of West Tallinn Central Hospital
City
Tallinn
ZIP/Postal Code
10617
Country
Estonia
Facility Name
West Tallinn Central Hospital
City
Tallinn
ZIP/Postal Code
10617
Country
Estonia
Facility Name
X- Ray Department of West Tallinn Central Hospital
City
Tallinn
ZIP/Postal Code
10617
Country
Estonia
Facility Name
X-Ray Department of West Tallinn Central Hospital
City
Tallinn
ZIP/Postal Code
10617
Country
Estonia
Facility Name
Mammograaf OU (Endoscopy Only)
City
Tallinn
ZIP/Postal Code
13419
Country
Estonia
Facility Name
ECG Unit, East Tallinn Central Hospital
City
Tallin
ZIP/Postal Code
10138
Country
Estonia
Facility Name
CHU Amiens PICARDIE - Hopital SUD
City
Amiens Cedex 1
ZIP/Postal Code
80054
Country
France
Facility Name
Hopital Saint Andre
City
Bordeaux cedex
ZIP/Postal Code
33075
Country
France
Facility Name
Hopital Beaujon
City
Clichy Cedex
ZIP/Postal Code
92110
Country
France
Facility Name
Hotel-Dieu CHU Nantes
City
Nantes cedex 01
ZIP/Postal Code
44093
Country
France
Facility Name
Hopital Saint Antoine - Service de Gastroenterologie
City
Paris cedex 12
ZIP/Postal Code
75571
Country
France
Facility Name
Hopital Saint Louis - Service d'hepato-gastoenterologie
City
Paris
ZIP/Postal Code
75010
Country
France
Facility Name
Hopital Saint Louis
City
Paris
ZIP/Postal Code
75010
Country
France
Facility Name
C.H.U. de Reims - Hôpital Robert Debré
City
Reims cedex
ZIP/Postal Code
51092
Country
France
Facility Name
Hopital Nord
City
Saint Priest en Jarez
ZIP/Postal Code
42270
Country
France
Facility Name
Universitaetsklinikum Schleswig-Holstein, Campus Kiel
City
Kiel
State/Province
Schlewig Holstein
ZIP/Postal Code
24105
Country
Germany
Facility Name
Universitaetsmedizin Berlin, Charite Campus Virchow-Klinikum,
City
Berlin
ZIP/Postal Code
13353
Country
Germany
Facility Name
Universitätsklinikum Halle
City
Halle
ZIP/Postal Code
06120
Country
Germany
Facility Name
Medizinische Hochschule Hannover
City
Hannover
ZIP/Postal Code
30625
Country
Germany
Facility Name
Klinikum Lüneburg/Abteilung Gastroenterologie
City
Lüneburg
ZIP/Postal Code
21339
Country
Germany
Facility Name
Gastroenterologische Gemeinschaftspraxis Minden
City
Minden
ZIP/Postal Code
32423
Country
Germany
Facility Name
Universitaetsklinikum Ulm
City
Ulm
ZIP/Postal Code
89081
Country
Germany
Facility Name
Dr Rethy Pal Korhaz-Rendelointezet, III Belgyogyaszat
City
Bekescsaba
ZIP/Postal Code
5600
Country
Hungary
Facility Name
Szent Margit Korhaz - III Belgyogyaszat
City
Budapest
ZIP/Postal Code
1032
Country
Hungary
Facility Name
Peterfy Sandor Utcai Korhaz Rendelointezet es Baleseti Kozpont
City
Budapest
ZIP/Postal Code
1076
Country
Hungary
Facility Name
Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak
City
Budapest
ZIP/Postal Code
1125
Country
Hungary
Facility Name
Pannonia Maganorvosi Centrum Kft.
City
Budapest
ZIP/Postal Code
H-1135
Country
Hungary
Facility Name
Debreceni Egyetem Klinikai Kozpont, Belgyogyaszati Intezet Gasztroenterologiai Tanszek
City
Debrecen
ZIP/Postal Code
4032
Country
Hungary
Facility Name
Bekes Megyei Pandy Kalman Korhaz III. Gasztroenterologiai Osztaly
City
Gyula
ZIP/Postal Code
5700
Country
Hungary
Facility Name
Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz
City
Miskolc
ZIP/Postal Code
3526
Country
Hungary
Facility Name
Karolina Korhaz
City
Mosonmagyarovar
ZIP/Postal Code
9200
Country
Hungary
Facility Name
Pecsi Tudomanyegyetem Klinikai Kozpont
City
Pecs
ZIP/Postal Code
7624
Country
Hungary
Facility Name
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont, I. Sz. Belgyogyaszati Klinika
City
Szeged
ZIP/Postal Code
6720
Country
Hungary
Facility Name
Javorszky Odon Korhaz
City
Vac
ZIP/Postal Code
2600
Country
Hungary
Facility Name
Rambam Health Care Campus
City
Haifa
ZIP/Postal Code
31096
Country
Israel
Facility Name
Rabin Medical Center, Beilinson campus
City
Petah Tikva
ZIP/Postal Code
49100
Country
Israel
Facility Name
Kaplan Medical Center
City
Rehovot
ZIP/Postal Code
76100
Country
Israel
Facility Name
Istituto Clinico Humanitas IRCSS
City
Rozzano
State/Province
Milano
ZIP/Postal Code
20089
Country
Italy
Facility Name
AOR Villa Sofia-Cervello
City
Palermo
State/Province
PA
ZIP/Postal Code
90146
Country
Italy
Facility Name
AOU Mater Domini - U.O. Fisiopatologia Digestiva
City
Catanzaro
ZIP/Postal Code
88100
Country
Italy
Facility Name
Aichi Medical University Hospital
City
Nagakute
State/Province
Aichi
ZIP/Postal Code
480-1195
Country
Japan
Facility Name
Hokkaido P.W.F.A.C Sapporo-Kosei general Hospital
City
Sapporo
State/Province
Hokkaido
ZIP/Postal Code
060-0033
Country
Japan
Facility Name
The Hospital of Hyogo College of Medicine
City
Nishinomiya
State/Province
Hyogo
ZIP/Postal Code
663-8501
Country
Japan
Facility Name
National Hospital Organization Mito Medical Center
City
Higashi-ibaraki-gun
State/Province
Ibaraki
ZIP/Postal Code
311-3193
Country
Japan
Facility Name
Sameshima Hospital
City
Kagoshima-shi
State/Province
Kagoshima
ZIP/Postal Code
892-0846
Country
Japan
Facility Name
Kuniyoshi Hospital
City
Kochi-shi
State/Province
Kochi
ZIP/Postal Code
780-0901
Country
Japan
Facility Name
National Hospital Organization Sendai Medical Center
City
Sendai
State/Province
Miyagi
ZIP/Postal Code
983-8520
Country
Japan
Facility Name
Osaka Medical College Hospital
City
Takatsuki-shi
State/Province
Osaka
ZIP/Postal Code
569-8686
Country
Japan
Facility Name
Shiga University of Medical Science Hospital
City
Otsu-shi
State/Province
Shiga
ZIP/Postal Code
520-2192
Country
Japan
Facility Name
Tokyo Medical And Dental University Hospital, Faculty of Medicine
City
Bunkyo-ku
State/Province
Tokyo
ZIP/Postal Code
113-8519
Country
Japan
Facility Name
Tokai University Hachioji Hospital
City
Hachioji
State/Province
Tokyo
ZIP/Postal Code
192-0032
Country
Japan
Facility Name
Kitasato University Kitasato Institute Hospital
City
Minato-ku
State/Province
Tokyo
ZIP/Postal Code
108-8642
Country
Japan
Facility Name
NTT Medical Center Tokyo
City
Shinagawa-ku
State/Province
Tokyo
ZIP/Postal Code
141-8625
Country
Japan
Facility Name
Showa University Hospital
City
Shinagawa-ku
State/Province
Tokyo
ZIP/Postal Code
142-8666
Country
Japan
Facility Name
Keio University Hospital
City
Shinjuku-ku
State/Province
Tokyo
ZIP/Postal Code
160-8582
Country
Japan
Facility Name
Chiba University Hospital
City
Chiba
ZIP/Postal Code
260-8677
Country
Japan
Facility Name
Toho University Sakura Medical Center
City
Chiba
ZIP/Postal Code
285-8741
Country
Japan
Facility Name
Kurume University Hospital
City
Fukuoka
ZIP/Postal Code
830-0011
Country
Japan
Facility Name
Hiroshima University Hospital
City
Hiroshima
ZIP/Postal Code
734-8551
Country
Japan
Facility Name
Osaka City University Hospital
City
Osaka
ZIP/Postal Code
545-8586
Country
Japan
Facility Name
Hanyang University Guri Hospital
City
Guri-si
State/Province
Gyeonggi-do
ZIP/Postal Code
471-701
Country
Korea, Republic of
Facility Name
KyungHee University Hospital
City
Seoul
State/Province
Republic of Korea
ZIP/Postal Code
130-872
Country
Korea, Republic of
Facility Name
Gachon University Gil Medical Center
City
Incheon
ZIP/Postal Code
405-760
Country
Korea, Republic of
Facility Name
Kyung Hee University Hospital
City
Seoul
ZIP/Postal Code
02447
Country
Korea, Republic of
Facility Name
Samsung Medical Center
City
Seoul
ZIP/Postal Code
06351
Country
Korea, Republic of
Facility Name
Seoul National University Hospital,
City
Seoul
ZIP/Postal Code
110-744
Country
Korea, Republic of
Facility Name
ECG room Clinic Linezers (ECG only) Riga East University Hospital
City
Riga
ZIP/Postal Code
LV-1006
Country
Latvia
Facility Name
X-Ray Department, Clinic Linezers (radiology only)
City
Riga
ZIP/Postal Code
LV-1006
Country
Latvia
Facility Name
Digestive Diseases Center GASTRO
City
Riga
ZIP/Postal Code
LV1006
Country
Latvia
Facility Name
VU University Medical Center (VUMC)
City
Amsterdam
ZIP/Postal Code
1081 HV
Country
Netherlands
Facility Name
Academic Medical Centre
City
Amsterdam
ZIP/Postal Code
1105 AZ
Country
Netherlands
Facility Name
University Medical Center Groningen (UMCG)
City
Groningen
ZIP/Postal Code
9713 GZ
Country
Netherlands
Facility Name
Leiden University Medical Center (LUMC)
City
Leiden
ZIP/Postal Code
2333 ZA
Country
Netherlands
Facility Name
Shakespeare Specialist Group
City
Milford
State/Province
Auckland
ZIP/Postal Code
0620
Country
New Zealand
Facility Name
Tauranga Hospital
City
Tauranga
State/Province
Bay of Plenty
ZIP/Postal Code
3143
Country
New Zealand
Facility Name
Christchurch Hospital
City
Christchurch
State/Province
Canterbury Region
ZIP/Postal Code
8011
Country
New Zealand
Facility Name
Auckland City Hospital
City
Auckland
ZIP/Postal Code
1023
Country
New Zealand
Facility Name
Southern District Health Board
City
Dunedin
ZIP/Postal Code
9016
Country
New Zealand
Facility Name
Waikato Hospital
City
Hamilton
ZIP/Postal Code
3240
Country
New Zealand
Facility Name
P3 Research Limited
City
Wellington
ZIP/Postal Code
6021
Country
New Zealand
Facility Name
Pacific Radiology (X-rays only)
City
Wellington
ZIP/Postal Code
6021
Country
New Zealand
Facility Name
Bowen Hospital
City
Wellington
ZIP/Postal Code
6035
Country
New Zealand
Facility Name
Centrum Medyczne Szpital Sw. Rodziny Sp. z o. o.
City
Lodz
State/Province
Iodzkie
ZIP/Postal Code
90-302
Country
Poland
Facility Name
Centrum Endoskopii Zabiegowej, Poradnia Chorob Jelitowych, Szpital Uniwersytecki nr 2 im
City
Bydgoszcz
State/Province
Kujawsko-pomorskie
ZIP/Postal Code
85-168
Country
Poland
Facility Name
Klinika Chorob Wewnetrznych i Gastroenterologii z
City
Warszawa
State/Province
Mazowieckie
ZIP/Postal Code
02-507
Country
Poland
Facility Name
H-T. Centrum Medyczne - ENDOTERAPIA
City
Tychy
State/Province
Slaskie
ZIP/Postal Code
43-100
Country
Poland
Facility Name
Gabinet Lekarski - Janusz Rudzinski
City
Bydgoszcz
ZIP/Postal Code
85-681
Country
Poland
Facility Name
Gabinet Endoskopii Przewodu Pokarmowego
City
Krakow
ZIP/Postal Code
31-009
Country
Poland
Facility Name
Oddzial Kliniczny Gastroenterologii Ogólnej i Onkologicznej, Uniwersytecki Szpital
City
Lodz
ZIP/Postal Code
90-153
Country
Poland
Facility Name
Endoskopia Sp. Z O.O.
City
Sopot
ZIP/Postal Code
81-756
Country
Poland
Facility Name
Nzoz Vivamed
City
Warszawa
ZIP/Postal Code
03-580
Country
Poland
Facility Name
Lexmedica
City
Wroclaw
ZIP/Postal Code
53-114
Country
Poland
Facility Name
Cabinet Particular Policlinic Algomed Srl
City
Timisoara
State/Province
Timis
ZIP/Postal Code
300002
Country
Romania
Facility Name
Spitalul Universitar de Urgenta Bucharest
City
Bucuresti
ZIP/Postal Code
050098
Country
Romania
Facility Name
Municipal Institution of Healthcare City Clinical Hospital 12,
City
Saratov
State/Province
Russia
ZIP/Postal Code
410039
Country
Russian Federation
Facility Name
Federal state budget institution "State scientific centre of coloproctology"
City
Moscow
ZIP/Postal Code
123423
Country
Russian Federation
Facility Name
State Budget Institution of Healthcare Nizhniy Novgorod Regional Clinical Hospital named after N. A.
City
Nizhniy Novgorod
ZIP/Postal Code
603126
Country
Russian Federation
Facility Name
Federal state Institution "Sibirian regional Medical centre of Federal Medicobiologic Agency",
City
Novosibirsk,
ZIP/Postal Code
630068
Country
Russian Federation
Facility Name
Municipal Budget Institution of Healthcare of Novosibirsk " City Clinical Hospital No 12"
City
Novosibirsk
ZIP/Postal Code
630084
Country
Russian Federation
Facility Name
State Budget Educational Institution of Higher Professional Education
City
Novosibirsk
ZIP/Postal Code
630091
Country
Russian Federation
Facility Name
Federal State Budgetary Institution "Scientific Research Institute of Physiology and Fundamental
City
Novosibirsk
ZIP/Postal Code
630117
Country
Russian Federation
Facility Name
Non-State Healthcare Institution "Road Clinical Hospital at the station Samara"
City
Samara
ZIP/Postal Code
443029
Country
Russian Federation
Facility Name
Limited Liability Company Medical Company "Hepatolog"
City
Samara
ZIP/Postal Code
443063
Country
Russian Federation
Facility Name
Limited Liability Company Medical Company "Hepatolog"
City
Samara
ZIP/Postal Code
443093
Country
Russian Federation
Facility Name
Samara Diagnostic center, X-ray Department
City
Samara
ZIP/Postal Code
443093
Country
Russian Federation
Facility Name
State budget institution of healthcare of Yaroslavl region Regional clinical hospital
City
Yaroslavl
ZIP/Postal Code
150062
Country
Russian Federation
Facility Name
Clinical Centre of Serbia, Clinic for Gastroenterology and Hepatology
City
Belgrade
State/Province
Serbia, Europe
ZIP/Postal Code
11000
Country
Serbia
Facility Name
Clinical Hospital Centre Zvezdara
City
Belgrade
ZIP/Postal Code
11000
Country
Serbia
Facility Name
Military Medical Academy Belgrade
City
Belgrade
ZIP/Postal Code
11000
Country
Serbia
Facility Name
Clinical Centre of Kragujevac
City
Kragujevac
ZIP/Postal Code
34000
Country
Serbia
Facility Name
Clinical Centre of Vojvodina, Clinic for Gastroenterology and Hepatology
City
Novi Sad
ZIP/Postal Code
21000
Country
Serbia
Facility Name
Clinical Centre of Vojvodina, Emergency Internal Medicine Division
City
Novi Sad
ZIP/Postal Code
21000
Country
Serbia
Facility Name
"General Hospital ""Djordje Joanovic""
City
Zrenjanin
ZIP/Postal Code
23000
Country
Serbia
Facility Name
Medak s.r.o.
City
Bratislava
ZIP/Postal Code
851 01
Country
Slovakia
Facility Name
KM Management spol. s.r.o.
City
Nitra
ZIP/Postal Code
949 01
Country
Slovakia
Facility Name
Aura SA, s.r.o.
City
Nove Mesto nad Vahom
ZIP/Postal Code
91501
Country
Slovakia
Facility Name
Gastro I., s.r.o.
City
Presov
ZIP/Postal Code
080 01
Country
Slovakia
Facility Name
Dr John Philip Wright
City
Claremont
State/Province
Cape Town
ZIP/Postal Code
7708
Country
South Africa
Facility Name
Chris Hani Baragwanath Academic Hospital
City
Johannesburg
State/Province
Gauteng
ZIP/Postal Code
2013
Country
South Africa
Facility Name
Panorama MediClinic
City
Cape Town
State/Province
Western Cape
ZIP/Postal Code
7500
Country
South Africa
Facility Name
Louis Leipoldt Medical Centre
City
Cape Town
State/Province
Western Cape
ZIP/Postal Code
7530
Country
South Africa
Facility Name
Endocare Research Centre
City
Western Cape
ZIP/Postal Code
7646
Country
South Africa
Facility Name
Hospital Universitari de Bellvitge, Servicio de Digestivo
City
L'Hospitalet de Llobregat
State/Province
Barcelona
ZIP/Postal Code
08907
Country
Spain
Facility Name
Hospital Clinic i Provincial de Barcelona
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Facility Name
Hospital Clinico San Carlos
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Hospital Universitario de Fuenlabrada
City
Madrid
ZIP/Postal Code
28942
Country
Spain
Facility Name
National Taiwan University Hospital
City
Taipei City
ZIP/Postal Code
10002
Country
Taiwan
Facility Name
Internal Medicine Center of Crimean Republic Institution"Clinical Territorial Medical Community"
City
Simferopol
State/Province
Ar Krym
ZIP/Postal Code
95017
Country
Ukraine
Facility Name
Regional Municipal Institution "Chernivtsi Regional Clinical Hospital"
City
Chernivtsi
ZIP/Postal Code
58001
Country
Ukraine
Facility Name
Regional Municipal Institution Chernivtsi Regional Clinical Hospital,
City
Chernivtsi
ZIP/Postal Code
58001
Country
Ukraine
Facility Name
State Institution "Institute of Gastroenterology of the National Academy of Medical Sciences of
City
Dniepropetrovsk
ZIP/Postal Code
49074
Country
Ukraine
Facility Name
Municipal Healthcare Institution Kharkiv City Clinical Hospital #2, Proctology Department
City
Kharkiv
ZIP/Postal Code
61037
Country
Ukraine
Facility Name
State Institution "National L.T. Malaya Therapy Institute of National Academy of
City
Kharkiv
ZIP/Postal Code
61039
Country
Ukraine
Facility Name
Kyiv Municipal Clinical Hospital #18, Proctology Department
City
Kyiv
ZIP/Postal Code
01030
Country
Ukraine
Facility Name
LTD "St. Paraskeva Medical Center"
City
Lviv
ZIP/Postal Code
79019
Country
Ukraine
Facility Name
Municipal City Clinical Hospital of the Emergency Medical Care, 1-st Therapy Department of hospital,
City
Lviv
ZIP/Postal Code
79059
Country
Ukraine
Facility Name
SI "Railway Hospital of the SI "Odesa Railway"", Polyclinic Department,
City
Odesa
ZIP/Postal Code
65010
Country
Ukraine
Facility Name
Municipal Institution "Odesa Regional Clinical Hospital"
City
Odesa
ZIP/Postal Code
65025
Country
Ukraine
Facility Name
SI "District Clin. Hosp.of Uzhgorod station (STSA "Lviv Railway", Therapy Dep., SBHEI "Uzhgorod Nat.
City
Uzhgorod
ZIP/Postal Code
88009
Country
Ukraine
Facility Name
Vinnytsia Regional Clinical Hospital for Invalids of the Great Patriotic War, Therapy Department #2,
City
Vinnytsia
ZIP/Postal Code
21005
Country
Ukraine
Facility Name
Motor-Sich clinic, LLC
City
Zaporizhzhia
ZIP/Postal Code
69068
Country
Ukraine
Facility Name
Minicipal Institution City Hospital 7, Therapevtic Department,
City
Zaporizhzhia
ZIP/Postal Code
69118
Country
Ukraine
Facility Name
Municipal Institution "City Hospital #7", Zaporizhzhia State Medical University
City
Zaporizhzhia
ZIP/Postal Code
69118
Country
Ukraine
Facility Name
Addenbrooke's Hospital-Cambridge University Hospitals NHS Foundation Trust
City
Cambridge
State/Province
Cambridgeshire
ZIP/Postal Code
CB20QQ
Country
United Kingdom
Facility Name
Department of Gastroenterology, Old Building
City
Bristol
State/Province
England
ZIP/Postal Code
BS2 8HW
Country
United Kingdom
Facility Name
University College Hospital
City
London
State/Province
Greater London
ZIP/Postal Code
NW1 2BU
Country
United Kingdom
Facility Name
NWLH NHS trust
City
Harrow
State/Province
Middlesex
ZIP/Postal Code
HA1 3UJ
Country
United Kingdom
Facility Name
The North West London Hospitals NHS Trust
City
Harrow
State/Province
Middlesex
ZIP/Postal Code
HA1 3UJ
Country
United Kingdom
Facility Name
Norfolk and Norwich University Hospital
City
Norwich
State/Province
Norfolk
ZIP/Postal Code
NR4 7UY
Country
United Kingdom
Facility Name
Addenbrooke's Hospital
City
Cambridge
ZIP/Postal Code
CB2 0QQ
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
36342120
Citation
Lichtenstein GR, Bressler B, Francisconi C, Vermeire S, Lawendy N, Salese L, Sawyerr G, Shi H, Su C, Judd DT, Jones T, Loftus EV. Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program. Inflamm Bowel Dis. 2023 Jan 5;29(1):27-41. doi: 10.1093/ibd/izac084.
Results Reference
derived
PubMed Identifier
36336750
Citation
Hudesman DP, Torres J, Salese L, Woolcott JC, Mundayat R, Su C, Mosli MH, Allegretti JR. Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program. Patient. 2023 Mar;16(2):95-103. doi: 10.1007/s40271-022-00603-w. Epub 2022 Nov 7.
Results Reference
derived
PubMed Identifier
35648151
Citation
Winthrop KL, Vermeire S, Long MD, Panes J, Ng SC, Kulisek N, Mundayat R, Lawendy N, Vranic I, Modesto I, Su C, Melmed GY. Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. Inflamm Bowel Dis. 2023 Jan 5;29(1):85-96. doi: 10.1093/ibd/izac063.
Results Reference
derived
PubMed Identifier
35574426
Citation
Vavricka SR, Greuter T, Cohen BL, Reinisch W, Steinwurz F, Fellmann M, Guo X, Lawendy N, Paulissen J, Peyrin-Biroulet L. Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study. Therap Adv Gastroenterol. 2022 May 10;15:17562848221090834. doi: 10.1177/17562848221090834. eCollection 2022.
Results Reference
derived
PubMed Identifier
35380740
Citation
Mukherjee A, Tsuchiwata S, Nicholas T, Cook JA, Modesto I, Su C, D'Haens GR, Sandborn WJ. Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies. Clin Pharmacol Ther. 2022 Jul;112(1):90-100. doi: 10.1002/cpt.2601. Epub 2022 Apr 27.
Results Reference
derived
PubMed Identifier
34614208
Citation
Feagan BG, Khanna R, Sandborn WJ, Vermeire S, Reinisch W, Su C, Salese L, Fan H, Paulissen J, Woodworth DA, Niezychowski W, Sands BE. Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials. Aliment Pharmacol Ther. 2021 Dec;54(11-12):1442-1453. doi: 10.1111/apt.16626. Epub 2021 Oct 6.
Results Reference
derived
PubMed Identifier
34165201
Citation
Farraye FA, Qazi T, Kotze PG, Moore GT, Mundayat R, Lawendy N, Sharma PP, Judd DT. The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme. Aliment Pharmacol Ther. 2021 Aug;54(4):429-440. doi: 10.1111/apt.16439. Epub 2021 Jun 24.
Results Reference
derived
PubMed Identifier
34035832
Citation
Rubin DT, Reinisch W, Greuter T, Kotze PG, Pinheiro M, Mundayat R, Maller E, Fellmann M, Lawendy N, Modesto I, Vavricka SR, Lichtenstein GR. Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis. Therap Adv Gastroenterol. 2021 May 16;14:17562848211005708. doi: 10.1177/17562848211005708. eCollection 2021.
Results Reference
derived
PubMed Identifier
33884415
Citation
Panes J, Vermeire S, Dubinsky MC, Loftus EV, Lawendy N, Wang W, Salese L, Su C, Modesto I, Guo X, Colombel JF. Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials. J Crohns Colitis. 2021 Nov 8;15(11):1852-1863. doi: 10.1093/ecco-jcc/jjab065.
Results Reference
derived
PubMed Identifier
33684552
Citation
Sandborn WJ, Peyrin-Biroulet L, Sharara AI, Su C, Modesto I, Mundayat R, Gunay LM, Salese L, Sands BE. Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status. Clin Gastroenterol Hepatol. 2022 Mar;20(3):591-601.e8. doi: 10.1016/j.cgh.2021.02.043. Epub 2021 Mar 6.
Results Reference
derived
PubMed Identifier
33513294
Citation
Vong C, Martin SW, Deng C, Xie R, Ito K, Su C, Sandborn WJ, Mukherjee A. Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis. Clin Pharmacol Drug Dev. 2021 Mar;10(3):229-240. doi: 10.1002/cpdd.899. Epub 2021 Jan 29.
Results Reference
derived
PubMed Identifier
33324993
Citation
Curtis JR, Regueiro M, Yun H, Su C, DiBonaventura M, Lawendy N, Nduaka CI, Koram N, Cappelleri JC, Chan G, Modesto I, Lichtenstein GR. Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan(R) Administrative Claims Database With Tofacitinib Trial Data. Inflamm Bowel Dis. 2021 Aug 19;27(9):1394-1408. doi: 10.1093/ibd/izaa289.
Results Reference
derived
PubMed Identifier
33039585
Citation
Colombel JF, Osterman MT, Thorpe AJ, Salese L, Nduaka CI, Zhang H, Lawendy N, Friedman GS, Quirk D, Su C, Reinisch W. Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 Jan;20(1):116-125.e5. doi: 10.1016/j.cgh.2020.10.004. Epub 2020 Oct 9.
Results Reference
derived
PubMed Identifier
32870265
Citation
Sands BE, Colombel JF, Ha C, Farnier M, Armuzzi A, Quirk D, Friedman GS, Kwok K, Salese L, Su C, Taub PR. Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management. Inflamm Bowel Dis. 2021 May 17;27(6):797-808. doi: 10.1093/ibd/izaa227.
Results Reference
derived
PubMed Identifier
32816215
Citation
Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20. Erratum In: Dig Dis Sci. 2020 Oct 10;:
Results Reference
derived
PubMed Identifier
32766762
Citation
Lichtenstein GR, Rogler G, Ciorba MA, Su C, Chan G, Pedersen RD, Lawendy N, Quirk D, Nduaka CI, Thorpe AJ, Panes J. Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program. Inflamm Bowel Dis. 2021 May 17;27(6):816-825. doi: 10.1093/ibd/izaa199.
Results Reference
derived
PubMed Identifier
31599001
Citation
Sandborn WJ, Panes J, Sands BE, Reinisch W, Su C, Lawendy N, Koram N, Fan H, Jones TV, Modesto I, Quirk D, Danese S. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment Pharmacol Ther. 2019 Nov;50(10):1068-1076. doi: 10.1111/apt.15514. Epub 2019 Oct 9.
Results Reference
derived
PubMed Identifier
31077827
Citation
Sands BE, Taub PR, Armuzzi A, Friedman GS, Moscariello M, Lawendy N, Pedersen RD, Chan G, Nduaka CI, Quirk D, Salese L, Su C, Feagan BG. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 Jan;18(1):123-132.e3. doi: 10.1016/j.cgh.2019.04.059. Epub 2019 May 8.
Results Reference
derived
PubMed Identifier
30476584
Citation
Sandborn WJ, Panes J, D'Haens GR, Sands BE, Su C, Moscariello M, Jones T, Pedersen R, Friedman GS, Lawendy N, Chan G. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. Clin Gastroenterol Hepatol. 2019 Jul;17(8):1541-1550. doi: 10.1016/j.cgh.2018.11.035. Epub 2018 Nov 23.
Results Reference
derived
PubMed Identifier
29850873
Citation
Winthrop KL, Melmed GY, Vermeire S, Long MD, Chan G, Pedersen RD, Lawendy N, Thorpe AJ, Nduaka CI, Su C. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. Inflamm Bowel Dis. 2018 Sep 15;24(10):2258-2265. doi: 10.1093/ibd/izy131.
Results Reference
derived
PubMed Identifier
29743836
Citation
Motoya S, Watanabe M, Kim HJ, Kim YH, Han DS, Yuasa H, Tabira J, Isogawa N, Arai S, Kawaguchi I, Hibi T. Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies. Intest Res. 2018 Apr;16(2):233-245. doi: 10.5217/ir.2018.16.2.233. Epub 2018 Apr 30. Erratum In: Intest Res. 2018 Jul;16(3):499-501.
Results Reference
derived
PubMed Identifier
29028981
Citation
Panes J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A, Bayliss M, Maher S, Cappelleri JC, Bushmakin AG, Rubin DT. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. J Crohns Colitis. 2018 Jan 24;12(2):145-156. doi: 10.1093/ecco-jcc/jjx133. Erratum In: J Crohns Colitis. 2019 Jan 1;13(1):139-140.
Results Reference
derived
PubMed Identifier
28467869
Citation
Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panes J; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017 May 4;376(18):1723-1736. doi: 10.1056/NEJMoa1606910.
Results Reference
derived
Links:
URL
https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921096&StudyName=A%20Study%20Of%20Oral%20CP-690%2C550%20As%20A%20Maintenance%20Therapy%20For%20Ulcerative%20Colitis
Description
To obtain contact information for a study center near you, click here.

Learn more about this trial

A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis

We'll reach out to this number within 24 hrs